Biomarcadores podem orientar a escolha de imunobiológicos no tratamento da asma
Biomarkers may guide the choice of biologics in asthma treatment
Rosana Câmara Agondi
References
1. www.ginasthma.org [Internet]. Acessado em junho de 2020.
2. Hossain SF, Huang M, Ono N, Morita A, Kanaya S, Amin AU. Development of a biomarker database toward performing disease classification and finding disease interrelations. Database (Oxford) 2021;2021:baab011. https://doi.org/10.1093/database/baab011
2. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849-58.
3. Malinovschi A, Janson C, Borres M, Alving K. Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity. J Allergy Clin Immunol. 2016;138:1301-8.
4. Yang M, Hogan SP, Mahalingam S, Pope SM, Zimmermann N, Fulkerson P, et al. Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. J Allergy Clin Immunol. 2003;112:935-43.
